What is the current Hospital-Treated Gram-Negative Infections market size?

The Hospital-Treated Gram-Negative Infections market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driving future outlook.

What are the key drivers of the Hospital-Treated Gram-Negative Infections market?

Increasing antibiotic resistance and rising demand for effective treatments drive the market.

What are the major challenges facing the market?

High development costs and regulatory hurdles are significant challenges in the market.

Which regions are leading the Hospital-Treated Gram-Negative Infections market?

North America and Europe are the leading regions, with Asia-Pacific emerging as a key player.

Who are the top companies in the market?

Pfizer, Merck, and GSK are among the top companies, with a strong pipeline of products.

What future opportunities exist in the market?

Personalized medicine and innovative therapies offer significant future opportunities for growth.

What is the current regulatory landscape for the market?

Stringent regulations and oversight from agencies like the FDA shape the market, ensuring safety and efficacy.

Hospital-Treated Gram-Negative Infections Market Growing at CAGR — 2026 Report

Hospital-Treated Gram-Negative Infections by Type (/> Klebsiella, Acinetobacter, Coli, Cepacia, Pseudomonas, Serratia, Enterobacter, Others), by Application (/> Public Hospital, Private Hospital), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $13.8 million

CAGR: 7.1%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $13.8 million

CAGR: 7.1%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Hospital-Treated Gram-Negative Infections Market Size | CAGR 7.1 Forecast 2033

Hospital-Treated Gram-Negative Infections Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $13.8 million

CAGR: 7.1%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $13.8 million

CAGR: 7.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Hospital-Treated Gram-Negative Infections Market Overview

The Hospital-Treated Gram-Negative Infections market refers to the segment of the healthcare industry focused on treating gram-negative bacterial infections in hospital settings. As the Hospital-Treated Gram-Negative Infections market size is estimated to be around $12.4 billion, with a growth outlook that is promising, driven by an increasing incidence of gram-negative infections and a rising demand for effective treatments, the market forecast indicates a significant expansion in the industry. The primary drivers of this growth include the increasing prevalence of antibiotic-resistant gram-negative bacteria, the rising demand for novel therapeutics, and advancements in technology that enable more effective treatments. The industry expansion is expected to be fueled by the development of new antimicrobial agents and the growing awareness of the need for proper infection control practices in hospitals.

Loading chart…

The Hospital-Treated Gram-Negative Infections market is expected to experience a compound annual growth rate (CAGR) of around 7-8% during the forecast period from 2026 to 2033, driven by macro drivers such as the increasing incidence of gram-negative infections, the rising demand for novel therapeutics, and advancements in technology. The key forces shaping the industry include technology shifts, such as the development of novel antimicrobial agents, regulations, such as those related to antibiotic use and resistance, and competitive intensity, driven by the growing number of players in the market. The largest region in the Hospital-Treated Gram-Negative Infections market is currently North America, while the fastest-growing region is expected to be the Asia-Pacific region, driven by the increasing incidence of gram-negative infections and the growing demand for effective treatments in these regions.

Report Overview

Report Attribute	Details
Market size value in 2025	13.80 million
Revenue forecast in 2033	23.89 million
Growth rate	CAGR of 7.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Pfizer; AstraZeneca; Abbott; Lupin Pharmaceuticals; Istituto lusofarmaco d’italia; Adelco S.A; Zhejiang yuntao biotechnology co., Ltd; Alcon Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Hospital-Treated Gram-Negative Infections market is poised for significant growth, driven by increasing awareness and advancements in treatment options. The Hospital-Treated Gram-Negative Infections market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Rising prevalence of Gram-Negative Infections, particularly in hospital settings, is fueling demand for effective treatments, thereby driving the Hospital-Treated Gram-Negative Infections market forward.

Advances in diagnostic technologies and therapeutic options are improving patient outcomes, contributing to the growth of the Hospital-Treated Gram-Negative Infections market size and influencing the overall growth forecast.

Restraints2 items

Increasing antimicrobial resistance and the subsequent need for novel treatments pose significant challenges to the Hospital-Treated Gram-Negative Infections market, potentially hindering its growth forecast.

Stringent regulatory requirements and high development costs may deter companies from investing in the Hospital-Treated Gram-Negative Infections market, affecting the overall Hospital-Treated Gram-Negative Infections market size.

Opportunities2 items

The growing demand for personalized medicine and targeted therapies presents opportunities for companies to develop innovative treatments, driving growth in the Hospital-Treated Gram-Negative Infections market and enhancing its growth forecast.

Collaborations between pharmaceutical companies and research institutions can accelerate the development of effective treatments, further expanding the Hospital-Treated Gram-Negative Infections market size and improving patient outcomes.

Challenges2 items

The complexity of Gram-Negative Infections and the need for comprehensive treatment approaches pose significant challenges to healthcare providers, impacting the Hospital-Treated Gram-Negative Infections market and its growth forecast.

Ensuring equitable access to effective treatments, particularly in resource-constrained settings, remains a major challenge for the Hospital-Treated Gram-Negative Infections market, affecting its overall growth and Hospital-Treated Gram-Negative Infections market size.

Market Segmentation

Loading chart…

The Type segment in the Hospital-Treated Gram-Negative Infections market refers to the different classes of gram-negative infections, including pneumonia, urinary tract infections, and sepsis, among others. Understanding this segmentation is crucial for market taxonomy as it helps in identifying the specific areas of focus for treatment and drug development, ultimately contributing to the overall Hospital-Treated Gram-Negative Infections market size.

The Application segment in the Hospital-Treated Gram-Negative Infections market involves the various settings and methods through which treatments are applied, such as hospital settings, outpatient clinics, and long-term care facilities. Analyzing this segment is vital for Hospital-Treated Gram-Negative Infections segmentation as it provides insights into the demand for treatments in different healthcare environments, influencing market strategies and product development.

Hospital-Treated Gram-Negative Infections Segmentation Breakdown12 items

Type

/> Klebsiella

Acinetobacter

Coli

Cepacia

Pseudomonas

Serratia

Enterobacter

Others

Application

/> Public Hospital

Private Hospital

Regional Insights

Loading chart…

The Hospital-Treated Gram-Negative Infections market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 35% of the market share, driven by advanced infrastructure, high adoption rates of innovative treatments, and significant investments in research and development. The Asia Pacific region is expected to be the fastest-growing region, driven by growing demographics, increasing ecosystem maturity, and government policies supporting healthcare infrastructure development.

Key drivers for each region include: for North America, established healthcare infrastructure, high awareness of gram-negative infections, and strong research and development initiatives; for Europe, growing demand for effective treatments, increasing investments in healthcare, and stringent infection control policies; for Asia Pacific, rapidly growing healthcare infrastructure, increasing adoption of innovative treatments, and government initiatives to control infections; for Latin America, growing healthcare expenditure, increasing awareness of gram-negative infections, and improving infrastructure; and for Middle East & Africa, growing healthcare infrastructure, increasing adoption of advanced treatments, and government initiatives to develop healthcare ecosystem.

The regional forecast indicates that the Hospital-Treated Gram-Negative Infections market will experience significant growth in the Asia Pacific region, driven by growing demand for effective treatments and increasing investments in healthcare infrastructure. The market growth will be moderate in North America and Europe, driven by established healthcare infrastructure and high awareness of gram-negative infections. The Latin America and Middle East & Africa regions will experience relatively slower growth, driven by limited infrastructure and lower adoption rates of innovative treatments.

Competitive Landscape

The Hospital-Treated Gram-Negative Infections market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, and product innovation. The Hospital-Treated Gram-Negative Infections competitive landscape is driven by companies that prioritize regulatory approvals and certifications. Global players tend to dominate the market, while local companies focus on regional expansion and partnerships.

Key players in the market employ various strategies to differentiate themselves, including M&A, partnerships, and product launches. Companies focus on technology, service models, and channel strength to gain a competitive edge. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must adapt to changing market conditions and prioritize innovation, localization, and cost advantages.

Merck: regional expansion

Pfizer: innovation pipeline

AstraZeneca: premium pricing

Abbott: local manufacturing

Lupin Pharmaceuticals: OEM tie-ups

Istituto lusofarmaco d’italia: vertical integration

Key Hospital-Treated Gram-Negative Infections Companies9 items

Merck

Pfizer

AstraZeneca

Abbott

Lupin Pharmaceuticals

Istituto lusofarmaco d’italia

Adelco S.A

Zhejiang yuntao biotechnology co., Ltd

Alcon Laboratories

Market Ecosystem

The Hospital-Treated Gram-Negative Infections ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of treatments, as well as the provision of services and support. This ecosystem is characterized by a complex interplay of participants, each playing a distinct role in the delivery of care for hospital-treated gram-negative infections.

Raw material/component suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing antibacterial treatments

Technology providers — developing diagnostic tools and therapies

Distributors / channel partners — delivering treatments to healthcare facilities

Service providers / after-sales — offering support and training for healthcare professionals

End users / buyers — healthcare providers and patients receiving treatments

Regulators/standards bodies — overseeing approval and compliance processes

In the Hospital-Treated Gram-Negative Infections ecosystem, value flows through the development, production, and delivery of effective treatments. Control points, such as regulatory approvals and reimbursement decisions, influence adoption and accessibility. Dependency risks, including input constraints and standards compliance, can impact the availability of treatments. Furthermore, switching costs, partnerships, and interoperability requirements can affect the dynamics of the ecosystem, which may differ by region due to varying regulatory frameworks and healthcare systems, highlighting the need for a comprehensive value chain analysis.

Recent Industry Insights

The Hospital-Treated Gram-Negative Infections industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between pharmaceutical companies and research institutions have accelerated the development of novel therapies. Notable mergers and acquisitions have also taken place, with a focus on expanding product portfolios and strengthening market presence. Furthermore, several product and technology launches have been observed, including innovative diagnostic tools and antibiotic therapies. Regulatory changes have also impacted the industry, with updated guidelines for the treatment of gram-negative infections. A shift in consumer trends towards personalized medicine and increased awareness about antimicrobial resistance has driven the demand for effective treatments. Additionally, funding rounds and expansions have been secured by various companies to support research and development efforts in this critical area.

Analyst Overview

As the Lead Analyst for this study, my expert view on the Hospital-Treated Gram-Negative Infections market is that it presents a highly attractive opportunity for pharmaceutical companies and healthcare providers. The Hospital-Treated Gram-Negative Infections market outlook is expected to grow significantly due to the increasing prevalence of antibiotic-resistant infections. The competitive intensity in this market is moderate, with several key players vying for market share. In terms of long-term outlook, I foresee a positive trend driven by innovations in treatment options and rising demand for effective therapies.

The innovation landscape is evolving rapidly, with a focus on developing novel antibiotics and alternative treatments. However, the demand-supply balance is a key concern, as the supply of effective treatments is often outpaced by demand. Furthermore, key risk factors such as antibiotic resistance and regulatory challenges must be carefully managed to ensure the long-term sustainability of this market.

11 items

1. Executive Summary

2. Hospital-Treated Gram-Negative Infections Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hospital-Treated Gram-Negative Infections Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hospital-Treated Gram-Negative Infections Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Klebsiella

6.1.2. Acinetobacter

6.1.3. Coli

6.1.4. Cepacia

6.1.5. Pseudomonas

6.1.6. Serratia

6.1.7. Enterobacter

6.1.8. Others

6.2. Global Hospital-Treated Gram-Negative Infections Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Public Hospital

6.2.2. Private Hospital

6.3. Global Hospital-Treated Gram-Negative Infections Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hospital-Treated Gram-Negative Infections Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hospital-Treated Gram-Negative Infections Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Hospital-Treated Gram-Negative Infections Market Competition by Key Manufacturers

8.1. Global Hospital-Treated Gram-Negative Infections Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hospital-Treated Gram-Negative Infections: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. AstraZeneca

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbott

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Lupin Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Istituto lusofarmaco d’italia

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Adelco S.A

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Zhejiang yuntao biotechnology co., Ltd

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Alcon Laboratories

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hospital-Treated Gram-Negative Infections Market

Figure 4: Global Hospital-Treated Gram-Negative Infections Market: Drivers

Figure 5: Global Hospital-Treated Gram-Negative Infections Market: Challenges

Figure 6: Global Hospital-Treated Gram-Negative Infections Market: Trends

Figure 7: Global Hospital-Treated Gram-Negative Infections Market: Opportunity

Figure 8: Global Hospital-Treated Gram-Negative Infections Market: Restraint

Figure 9: Global Hospital-Treated Gram-Negative Infections Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Hospital-Treated Gram-Negative Infections Market Value (USD Million) By Region

Figure 15: Global Hospital-Treated Gram-Negative Infections Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Hospital-Treated Gram-Negative Infections Market Value (USD Million) By Region

Figure 23: Global Hospital-Treated Gram-Negative Infections Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Hospital-Treated Gram-Negative Infections Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Hospital-Treated Gram-Negative Infections Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Hospital-Treated Gram-Negative Infections Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Hospital-Treated Gram-Negative Infections Market Value (USD Million) By Region

Table 10: Global Hospital-Treated Gram-Negative Infections Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Hospital-Treated Gram-Negative Infections Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hospital-Treated Gram-Negative Infections Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hospital-Treated Gram-Negative Infections Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: AstraZeneca Basic Information And Sales Area

Table 35: AstraZeneca. Products Portfolio

Table 36: Abbott Basic Information And Sales Area

Table 37: Abbott. Products Portfolio

Table 38: Lupin Pharmaceuticals Basic Information And Sales Area

Table 39: Lupin Pharmaceuticals. Products Portfolio

Table 40: Istituto lusofarmaco d’italia Basic Information And Sales Area

Table 41: Istituto lusofarmaco d’italia. Products Portfolio

Table 42: Adelco S.A Basic Information And Sales Area

Table 43: Adelco S.A. Products Portfolio

Table 44: Zhejiang yuntao biotechnology co., Ltd Basic Information And Sales Area

Table 45: Zhejiang yuntao biotechnology co., Ltd. Products Portfolio

Table 46: Alcon Laboratories Basic Information And Sales Area

Table 47: Alcon Laboratories. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Type

Table 49: Global Market Share (%) By Type (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Hospital-Treated Gram-Negative Infections Market Value (USD Million) By Region

Table 53: Global Hospital-Treated Gram-Negative Infections Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Type

Table 56: North America Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Type

Table 59: Europe Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Type

Table 65: South America Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hospital-Treated Gram-Negative Infections Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.80 million
Revenue forecast in 2033	23.89 million
Growth rate	CAGR of 7.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Pfizer; AstraZeneca; Abbott; Lupin Pharmaceuticals; Istituto lusofarmaco d’italia; Adelco S.A; Zhejiang yuntao biotechnology co., Ltd; Alcon Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options